Periodic Reporting for period 1 - PANTREAT (Pancreatic cancer as a treatment target of Dwarfbody-Therapeutics)

The problems addressedThe spin off company Dwarfbody-Therapeutics has developed proprietary antibodies that target malignant signaling pathways in aggressive cancers. Currently the drug has been tested for esophageal cancer. However to bring the drug to the market, it is of...